Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not a deep response to treatment, promises better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone.
Health Professionals
Triplet Immunotherapy Shows Promise in Early-Phase Trial of Untreated Advanced Melanoma
The triplet combination of nivolumab, relatlimab, and ipilimumab offered promising response rates and survival outcomes in patients with untreated advanced melanoma, according to preliminary data from the nonrandomized phase 1/2 RELATIVITY-048 trial (Abstract 9504). Although the results require confirmation in larger randomized trials, the 4-year overall survival (OS) rate seen with the triplet regimen compares favorably with other nivolumab-based combinations in this setting.
Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma
Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
Targeted induction before immunotherapy shows limited benefit in advanced melanoma
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.